TAK - Takeda BLA for subcutaneous Entyvio for Crohn's accepted by FDA
2023-09-13 08:30:21 ET
More on Takeda Pharmaceutical
- Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
- Takeda: Upside Case Strengthening, Looking To 15x Earnings
- ImmunoGen inks deal with Takeda for cancer drug Elahere
- Takeda pulls marketing application for dengue vaccine in the U.S.
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Takeda BLA for subcutaneous Entyvio for Crohn's accepted by FDA